ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 332.30K | 315.90K | 287.00K | 260.10K | 244.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 332.30K | 315.90K | 287.00K | 260.10K | 244.10K |
| Cost of Revenue | 1.75M | 1.77M | 1.76M | 1.74M | 485.10K |
| Gross Profit | -1.42M | -1.46M | -1.47M | -1.48M | -240.90K |
| SG&A Expenses | 8.43M | 9.02M | 9.64M | 9.45M | 7.97M |
| Depreciation & Amortization | 2.19M | 2.23M | 2.15M | 2.30M | 2.27M |
| Other Operating Expenses | 279.80K | 285.50K | 291.60K | 261.10K | 202.30K |
| Total Operating Expenses | 14.22M | 14.46M | 14.78M | 14.72M | 11.68M |
| Operating Income | -13.89M | -14.14M | -14.49M | -14.46M | -11.43M |
| Income Before Tax | -31.16M | -31.41M | -34.77M | -35.87M | -18.03M |
| Income Tax Expenses | -4.29M | -4.30M | -4.30M | -4.30M | -43.80K |
| Earnings from Continuing Operations | -26.86 | -27.12 | -30.47 | -31.57 | -17.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.86M | -27.12M | -30.47M | -31.57M | -17.99M |
| EBIT | -13.89M | -14.14M | -14.49M | -14.46M | -11.43M |
| EBITDA | -12.00M | -12.21M | -12.64M | -12.45M | -9.52M |
| EPS Basic | -0.38 | -0.39 | -0.49 | -0.54 | -0.40 |
| Normalized Basic EPS | -0.13 | -0.13 | -0.17 | -0.21 | -0.23 |
| EPS Diluted | -0.39 | -0.39 | -0.49 | -0.55 | -0.40 |
| Normalized Diluted EPS | -0.13 | -0.13 | -0.17 | -0.21 | -0.23 |
| Average Basic Shares Outstanding | 283.92M | 281.56M | 256.46M | 224.14M | 192.64M |
| Average Diluted Shares Outstanding | 283.92M | 281.56M | 256.46M | 224.14M | 192.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
